Cambridge Innovation Capital — 2022 Investments
6 investments dated 2022 · listed companies and verified rows first · show all
Pretzel Therapeutics develops therapeutics targeting bioenergetic dysfunction and mitochondrial disease by addressing defects in mitochondrial DNA function and gene expression.
BiotechDeep TechHealthtechMedical Devices
Michal Minczuk(Co-Founder)inGabriel Martinez(Chief Scientific Officer & Co-Founder)Claes Gustafsson(Co-Founder)Maria Falkenberg(Co-Founder)Nils-Göran Larsson(Co-Founder)Gabriel Martinez, Ph.D.(Chief Scientific Officer & Co-Founder)
Co-investorsARCH Venture PartnersEIR VenturesGV (Google Ventures)HealthCap
Cambridge GaN Devices is a fabless semiconductor company that develops energy-efficient GaN-based power devices for sustainable electronics.
CleantechDeep TechEnergyHardwareSemiconductorsCambridge, GB
Fabio Necco(CEO)in
Co-investorsEMV CapitalIQ CapitalMartlet CapitalBritish Patient CapitalParkwalk Advisors
.jpeg){kind=logo}
Microbiotica is a clinical-stage biopharmaceutical company developing precision live biotherapeutic products derived from the human microbiome for immuno-oncology and inflammatory bowel disease.
BiotechDigital HealthHealthtechMedical DevicesCambridge, GB
Trevor Lawley(Co-founder and CSO)in
Co-investorsSeventure PartnersDCVC (Data Collective)
Nuclera provides multiplex protein screening technology for life science researchers, enabling faster access to and testing of proteins for drug discovery and development.
AI & Machine LearningBiotechDeep TechHardwareCambridge, US
Co-investorsBritish Business BankAmadeus Capital PartnersFuture Planet Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Botanical Ventures LimitedUnlikely AI
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.